当前位置: X-MOL首页全球导师 海外导师 › Brightling , Chris

研究领域

Immunopathogenesis of airway disease namely asthma, chronic obstructive pulmonary disease (COPD) and chronic cough

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Bafadhel M, McKenna S, Agbetile J, Fairs A, Desai D, Mistry V, Morley JP, Pancholi M, Pavord ID, Wardlaw AJ, Pashley CH, Brightling CE. Aspergillus fumigatus during stable state and exacerbations of COPD. Eur Respir J. 2013 Apr 18. [Epub ahead of print] Desai D, Newby C, Symon F, Haldar P, Shah S, Gupta S, Bafadhel M, Singapuri A, Siddiqui S, Woods J, Herath A, Anderson IK, Bradding P, Green R, Kulkarni N, Pavord I, Marshall RP, Sousa AR, May RD, Wardlaw AJ, Brightling CE. Elevated Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Severe Asthmatics. Am J Respir Crit Care Med. 2013 Apr 3. [Epub ahead of print] Berair R, Hollins F, Brightling C. Airway smooth muscle hypercontractility in asthma. J Allergy (Cairo). 2013;2013:185971. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, Menzies-Gow AN, Mansur AH, McSharry C. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol. 2013 Apr;131(4):1008-16. Desai D, Gupta S, Siddiqui S, Singapuri A, Monteiro W, Entwisle J, Visvanathan S, Parmar H, Kajekar R, Brightling CE. Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma. Respir Res 2013;14:17. Kuipers I, Louis R, Manise M, Dentener MA, Irvin CG, Janssen-Heininger YM, Brightling CE, Wouters EF, Reynaert NL. Increased glutaredoxin-1 and decreased protein S-glutathionylation in sputum of asthmatics. Eur Respir J 2013;41(2):469-72 Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med 2013;7(1):33-42 Barker BL, Brightling CE. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. Clin Sci (Lond) 2013;124(6):371-87 Singh SR, Sullo N, D'Agostino B, Brightling CE, Lambert DG. The effects of nociceptin peptide (N/OFQ)-receptor (NOP) system activation in the airways. Peptides 2013;39:36-46 Gibeon D, Batuwita K, Osmond M, Heaney LG, Brightling CE, Niven R, Mansur A, Chaudhuri R, Bucknall CE, Rowe A, Guo Y, Bhavsar PK, Chung KF, Menzies-Gow A. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest 2013;14(2):406-14. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;41(2):330-8

推荐链接
down
wechat
bug